How can myopia be controlled when only a small percentage of doctors attempt to control it?

Given the rapidly increasing use of GLP-1 agonist pharmacotherapy, it is important to continue to improve our understanding of the impact of these powerful medications, as clinical trials have thus far provided limited and conflicting evidence on potential retinal risks. Photo: Novo Nordisk. Click image to enlarge.  The substantial increase in glucagon-like peptide-1 (GLP-1)